Understanding the role of Cyclosporin A drops in control of ocular inflammation in acute cases of Stevens Johnson Syndrome

Evaluation of topical Cyclosporin A drops in control of ocular inflammation in acute Stevens Johnson Syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11036223

Enrollment

Registered

2016-10-03

Start date

2007-12-02

Completion date

Unknown

Last updated

2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Stevens-Johnson Syndrome Skin and Connective Tissue Diseases Stevens-Johnson syndrome

Interventions

Participants are randomly allocated to one of two groups. Those in group 1 are treated with topical Cyclosporin A 1% drops along with the standard regime, followed from the day one of presentation. Th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of acute Stevens Johnson Syndrome

Exclusion criteria

Exclusion criteria: 1. Pregnant females 2. Lactating females 3. Children below 2 years 4. Patients who refuse consent 5. Patients with known sensitivity to cyclosporin 6. Patients with cardiac, renal and hepatic failure

Design outcomes

Primary

Measure	Time frame
1. Degree of inflammation, assessed using grading score for inflammation (conjunctival hyperaemia) 2. Degree of corneal vascularisation, assessed using grading score for corneal vascularisation Measured pre-treatment and post treatment.	—

Secondary

Measure	Time frame
1. Any improvement in tear secretions, assessed using schirmer’s test 2. Ocular surface status, assessed using overall grading for ocular surface parameters Measured pre-treatment and post treatment.	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026